These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 17393394

  • 1. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 8. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N, Direskeneli H.
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [Abstract] [Full Text] [Related]

  • 9. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [Abstract] [Full Text] [Related]

  • 10. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.
    Wendling D, Streit G, Toussirot E, Prati C.
    Joint Bone Spine; 2008 Oct; 75(5):540-3. PubMed ID: 18674945
    [Abstract] [Full Text] [Related]

  • 11. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR.
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [Abstract] [Full Text] [Related]

  • 15. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 16. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Non tuberculous anti-TNF associated opportunistic infections].
    Marie I, Guglielmino E.
    Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.